Concepedia

Andreana Robertson

AR

9

Publications

2.3K

Citations

9

H-Index

2020

Active since

Affiliations

Novavax (United States)(Current)

Setshaba Research Centre

University of Cape Town

Centre for the AIDS Programme of Research in South Africa

Soweto CTC

Andreana Robertson is an author at Novavax (United States) specializing in vaccine development, covid-19, and vaccination.

ORCID

Top concepts

Publications per year

2020–2022

9

Publications

9

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech, Gary Albert, Iksung Cho et al. · New England Journal of Medicine · 2020 · 1.2K citations · Full text

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

Vivek Shinde, Sutika Bhikha, Zaheer Hoosain et al. · New England Journal of Medicine · 2021 · 652 citations · Full text

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial

Neil Formica, Raburn M. Mallory, Gary Albert et al. · PLoS Medicine · 2021 · 112 citations · Full text

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

Raburn M. Mallory, Neil Formica, Susan Pfeiffer et al. · The Lancet Infectious Diseases · 2022 · 78 citations · Full text

, , +7

Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial

Shabir A. Madhi, Dhayendre Moodley, Sherika Hanley et al. · The Lancet HIV · 2022 · 65 citations · Full text

Rows per page

1–5 of 9